TENAX THERAPEUTICS, INC.
TENX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TENX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TENX
Tenax Therapeutics is a development-stage pharmaceutical company focused on cardiopulmonary therapies, primarily advancing oral levosimendan for pulmonary hypertension with preserved ejection fraction (PH-HFpEF) through Phase 3 trials, while also holding imatinib for PAH as a deprioritized asset.
Key risk: Single product dependency
BioSniper Score
Based on 5 of 6 signals
Market Cap
$79.7M
Cash Runway
25.2 moLead Asset
imatinib (Preclinical)Next Catalyst
Phase3_Topline · Oct 30, 2028Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 5 clinical trials · 3 catalysts for TENAX THERAPEUTICS, INC..
Tenax Therapeutics is a development-stage pharmaceutical company focused on cardiopulmonary therapies, primarily advancing oral levosimendan for pulmonary hypertension with preserved ejection fraction (PH-HFpEF) through Phase 3 trials, while also holding imatinib for PAH as a deprioritized asset.
- Tenax is a development-stage company using a clinician-driven approach to develop novel cardiopulmonary therapies, with levosimendan as its prioritized candidate [sec · filed 2026-03-10].
- As of June 30, 2026, the company reported cash & equivalents of $118.0M, no revenue, and a net loss of -$17.8M [sec].
- Levosimendan and imatinib have already been approved in other indications and prescribed for more than 20 years, which the company believes supports their mechanisms of action [sec · filed 2026-03-10].
- The company is actively conducting the LEVEL and LEVEL-2 Phase 3 trials for levosimendan and has deprioritized a Phase 3 trial for imatinib [sec · filed 2026-03-10].
- Tenax will require substantial additional capital to complete development, regulatory approval, and potential commercialization of its product candidates [sec · filed 2026-03-10].
What works
- Levosimendan and imatinib are already approved in other indications and have over 20 years of real-world use, potentially reducing development risk [sec · filed 2026-03-10].
- The company employs a clinician-driven development approach led by key opinion leaders and heart failure experts, which may enhance trial design and targeting [sec · filed 2026-03-10].
- As of June 30, 2026, Tenax held $118.0M in cash and equivalents, providing a multi-year runway to advance its Phase 3 programs [sec].
What to weigh
- Tenax is limited to a small number of product opportunities, with survival dependent on success with levosimendan for PH-HFpEF [sec · filed 2026-03-10].
- The company will need substantial additional capital to complete the LEVEL and LEVEL-2 trials, regulatory processes, and commercialization; such funding may not be available on favorable terms [sec · filed 2026-03-10].
- Clinical trial results are preliminary and subject to change as more data becomes available, and discrete observations may not reflect final outcomes [sec · filed 2026-03-10].
- The company has deprioritized its imatinib program, concentrating risk on a single lead candidate [sec · filed 2026-03-10].
From the filings
Quoted directly from source documents.
Tenax is a development-stage company focused on cardiopulmonary therapies.
“development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.”
SEC filings · March 10, 2026
Levosimendan is the prioritized candidate; imatinib is deprioritized.
“We are currently actively conducting the LEVEL and LEVEL-2 clinical trials to evaluate levosimendan as our prioritized product candidate and have deprioritized a Phase 3 clinical trial of imatinib”
SEC filings · March 10, 2026
Both drugs have prior approval and long-term use in other indications.
“both levosimendan and imatinib have already been approved in other indications and prescribed around the world for more than 20 years”
SEC filings · March 10, 2026
Substantial additional capital is needed for development and commercialization.
“We will require substantial additional funding to further develop, file marketing authorization applications, and if approved, commercialize our product candidates”
SEC filings · March 10, 2026
Catalyst timeline
- 2028-10-30 · Phase3_Topline · levosimendan — Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens — Topline results from the pivotal Phase 3 trial of levosimendan for pulmonary hypertension with HFpEF will be a key value inflection point.
- 2029-03-01 · Phase3_Topline — Phase 3 Topline: A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103) — Topline data from the long-term extension study will provide additional safety and efficacy data for oral levosimendan.
- 2029-06-30 · Phase3_Topline · levosimendan — Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens — Second Phase 3 topline readout for levosimendan in pulmonary hypertension, potentially supporting regulatory submission.
Risks & what to watch (4)›
Key risks
- Single product dependency — Survival depends on success with levosimendan for PH-HFpEF; imatinib program is deprioritized [sec · filed 2026-03-10].
- Need for additional capital — Substantial funding required for trials, regulatory approval, and commercialization; may not be available on favorable terms [sec · filed 2026-03-10].
- Clinical trial uncertainty — Preliminary results may change with more data; discrete observations may not reflect final outcomes [sec · filed 2026-03-10].
- Limited product pipeline — Company is limited in the number of products it can pursue simultaneously [sec · filed 2026-03-10].
What to watch
- Topline data from the Phase 3 LEVEL trial for levosimendan in PH-HFpEF, expected around October 30, 2028 [catalyst].
- Topline data from the Phase 3 long-term extension study (TNX-103) for oral levosimendan, expected around March 1, 2029 [catalyst].
- Additional topline results from a second Phase 3 study of levosimendan in pulmonary hypertension, expected around June 30, 2029 [catalyst].
- Company's ability to secure additional financing to complete its development programs and potential commercialization efforts [sec · filed 2026-03-10].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run TENAX THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TENAX THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
25.2 months
D/E 0.07 · 0% dilution
Lead: Phase 3
4 candidates
3 upcoming, next in ~792d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 2.9%
- Days to cover
- 1.3
- Shares short
- 730,696
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TENX short interestGovernance
Frequently asked questions
What is the AI investment thesis for TENAX THERAPEUTICS, INC.?
Tenax Therapeutics is a development-stage pharmaceutical company focused on cardiopulmonary therapies, primarily advancing oral levosimendan for pulmonary hypertension with preserved ejection fraction (PH-HFpEF) through Phase 3 trials, while also holding imatinib for PAH as a deprioritized asset.
What is TENAX THERAPEUTICS, INC.'s lead drug candidate?
TENAX THERAPEUTICS, INC.'s most advanced tracked candidate is imatinib (Preclinical) for pulmonary arterial hypertension ("PAH").
What is TENAX THERAPEUTICS, INC.'s next catalyst?
TENAX THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens" — expected October 30, 2028.
Who is the CEO of TENAX THERAPEUTICS, INC.?
Mr. Christopher T. Giordano is the chief executive officer of TENAX THERAPEUTICS, INC. (TENX).
Where is TENAX THERAPEUTICS, INC. headquartered?
TENAX THERAPEUTICS, INC. (TENX) is headquartered in Chapel Hill, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.